170 related articles for article (PubMed ID: 23940523)
1. XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysis.
Shen XY; Lu FZ; Wu Y; Zhao LT; Lin ZF
PLoS One; 2013; 8(8):e69553. PubMed ID: 23940523
[TBL] [Abstract][Full Text] [Related]
2. XRCC3 Thr241Met is associated with response to platinum-based chemotherapy but not survival in advanced non-small cell lung cancer.
Qiu M; Xu L; Yang X; Ding X; Hu J; Jiang F; Xu L; Yin R
PLoS One; 2013; 8(10):e77005. PubMed ID: 24116196
[TBL] [Abstract][Full Text] [Related]
3. Predictive effect of XRCC3 Thr241Met polymorphism on platinum-based chemotherapy in lung cancer patients: meta-analysis.
Zhang W; Yan B; Jiang L
Tumour Biol; 2013 Dec; 34(6):3989-93. PubMed ID: 23990458
[TBL] [Abstract][Full Text] [Related]
4. [Effect of the XRCC1 and XRCC3 genetic polymorphisms on the efficacy of platinum-based chemotherapy in patients with advanced non-small cell lung cancer].
Xu C; Wang X; Zhang Y; Li L
Zhongguo Fei Ai Za Zhi; 2011 Dec; 14(12):912-7. PubMed ID: 22152690
[TBL] [Abstract][Full Text] [Related]
5. Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients.
Chen X; Sun H; Ren S; Kim Curran V; Zhang L; Zhou S; Zhang J; Zhou C
Clin Transl Oncol; 2012 Mar; 14(3):207-13. PubMed ID: 22374424
[TBL] [Abstract][Full Text] [Related]
6. Association between XRCC3 Thr241Met polymorphism and colorectal cancer risk.
Wang Z; Zhang W
Tumour Biol; 2013 Jun; 34(3):1421-9. PubMed ID: 23504553
[TBL] [Abstract][Full Text] [Related]
7. Association between XRCC3 Thr241Met polymorphism and risk of brain tumors: a meta-analysis.
Liu J; Zhou Z; Lai T; Yin J
Tumour Biol; 2014 Feb; 35(2):1083-7. PubMed ID: 24061639
[TBL] [Abstract][Full Text] [Related]
8. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
[TBL] [Abstract][Full Text] [Related]
9. DNA repair gene XRCC3 Thr241Met polymorphism and hepatocellular carcinoma risk.
Duan C; Zhang W; Lu J; Wu H; Liu M; Zhu W
Tumour Biol; 2013 Oct; 34(5):2827-34. PubMed ID: 23824570
[TBL] [Abstract][Full Text] [Related]
10. Association between the XRCC3 Thr241Met polymorphism and risk of colorectal cancer: a meta analysis of 5,193 cases and 6,645 controls.
Namazi A; Abedinzadeh M; Nourbaksh P; Neamatzadeh H
Asian Pac J Cancer Prev; 2015; 16(6):2263-8. PubMed ID: 25824748
[TBL] [Abstract][Full Text] [Related]
11. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
12. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Yang Y; Xian L
Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis.
Wu J; Liu J; Zhou Y; Ying J; Zou H; Guo S; Wang L; Zhao N; Hu J; Lu D; Jin L; Li Q; Wang JC
Clin Cancer Res; 2012 Jul; 18(14):3972-81. PubMed ID: 22705987
[TBL] [Abstract][Full Text] [Related]
14. DNA repair gene XRCC3 Thr241Met polymorphisms and lung cancer risk: a meta-analysis.
Bei L; Xiao-Dong T; Yu-Fang G; Jian-Ping S; Zhao-Yu Y
Bull Cancer; 2015 Apr; 102(4):332-9. PubMed ID: 25794597
[TBL] [Abstract][Full Text] [Related]
15. Association of XRCC3 Thr241Met polymorphism and leukemia risk: evidence from a meta-analysis.
Yan Y; Liang H; Li T; Guo S; Li M; Qin X; Li S
Leuk Lymphoma; 2014 Sep; 55(9):2130-4. PubMed ID: 24304418
[TBL] [Abstract][Full Text] [Related]
16. Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statement.
Li DJ; Xiao D
BMC Cancer; 2017 Jul; 17(1):501. PubMed ID: 28743242
[TBL] [Abstract][Full Text] [Related]
17. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
[TBL] [Abstract][Full Text] [Related]
18. Meta analysis of XRCC3 Thr241Met polymorphism and lung cancer susceptibility of populations in East Asia.
Xing ZS; Zhu G; Yang YL; Feng GQ; Ding GC
Asian Pac J Trop Med; 2014 Jun; 7(6):483-7. PubMed ID: 25066399
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis.
Yu SN; Liu GF; Li XF; Fu BH; Dong LX; Zhang SH
J Cell Biochem; 2017 Dec; 118(12):4782-4791. PubMed ID: 28520216
[TBL] [Abstract][Full Text] [Related]
20. Influence of methylenetetrahydrofolate reductase C677T polymorphism on the risk of lung cancer and the clinical response to platinum-based chemotherapy for advanced non-small cell lung cancer: an updated meta-analysis.
Zhu N; Gong Y; He J; Xia J; Chen X
Yonsei Med J; 2013 Nov; 54(6):1384-93. PubMed ID: 24142642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
